Abstracts cal disease in Singapore and Hong Kong from a payer perspective. METHODS: A decision-analytic model was developed to estimate the impact of vaccination with PCV13 relative to PCV7 and to PCV10 on invasive pneumococcal disease (IPD), pneumonia, and otitis media. Model inputs include disease incidence, sequelae, and mortality; serotype coverage; immunogenicity; direct and indirect effects; and costs. Specific local data were obtained from regional surveillance and published literature. Where local data were unavailable, proxy data were derived from published US sources. Vaccine costs assumed price parity to the private market unit price for PCV7 and were based on a four dose schedule. Costs and outcomes were discounted at 3%. RESULTS: Preliminary results demonstrated that PCV13 was dominant compared to PCV10 and compared to PCV7, both with and without indirect effects, in Singapore and in Hong Kong. The net cost savings per child vaccinated with PCV13 compared to PCV7 was S$7 in Singapore and HK$1352 in Hong Kong when including indirect effects. With direct effects only, the net cost savings per child vaccinated was S$1 and HK$4 in the respective countries. PCV13 direct effects would reduce IPD by 86% amongst vaccinated children in both regions. Results also indicated further reductions in pneumonia and otitis media burden with PCV13. CONCLUSIONS: These preliminary results suggest that pediatric national immunization programs with PCV13 in Singapore and in Hong Kong are expected to substantially decrease pneumococcal illness. In addition, the programs are expected to be cost-savings relative to PCV10 and to PCV7. OBJECTIVES: Determine cost-effectiveness and cost-utility of three treatment schemes (based on lopinavir [LPV/r], darunavir [DRV/r] and atazanavir [ATZ/r]) used in patients with HIV/AIDS after a first virological failure, in Colombia. METHODS: We designed a Markov model with 10 six-month cycles (5-year timeframe) based on efficacy measures obtained from published clinical trials. We estimated local direct costs from a payer perspective using 2009 official rates for drugs and lab tests, and real costs for AIDS-related complications (exchange rate Col$1968 per US$, January 2010). Utilities (in QALYs) were obtained from the Tufts CEA registry. Effectiveness was measured as further virological failures, need of "rescue therapy", AIDS-related complications, and deaths per 1000 patients (estimated through Monte Carlo probabilistic simulation). We applied a 5% discount rate for costs and QALYs. RESULTS: Average cost per patient was US$ 39,334 for DRV/r, US$ 41,825 for LPV/r and US$ 49,135 for ATZ/r. Five-year mortality was 5.9% in the DRV/r group, 7.6% for LPV/r and 8.0% for ATZ/r; there were 235 AIDS-related complications in the DRV/r group, 383 in the LPV/r group and 326 in ATZ/r. Rescue therapy was required in 85 occasions in the DRV/r group, 273 in the LPV/r group and 198 in the ATZ/r group, while there were 700 virological failures per 1000 patients in the DRV/r group, 1070 in LPV/r and 1080 in ATZ/r. Average QALYs gained in the five-year period were: DRV/r 3.92; LPV/r 3.81 and ATZ/r 3.84. Cost-utility and cost-effectiveness analysis show darunavir as the dominant alternative since the first year compared to atazanavir, and since the fourth year compared to lopinavir. One way sensitivity analyses did not modify the results significantly. CONCLUSIONS: In Colombia, initial treatment with darunavir in patients with a first antiretroviral therapy failure is less costly than with lopinavir or atazanavir and is significantly more effective.
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COST-EFFECTIVENESS OF 2009 PANDEMIC INFLUENZA A(H1N1) VACCINATION IN THE UNITED STATES
Prosser LA 1 , Lavelle TA 2 , Fiore A 3 , Bridges CB 3 , Reed C 3 , Jain S 3 , Dunham K 1 , Meltzer M 3 1 University of Michigan, Ann Arbor, MI, USA, 2 Harvard University, Boston, MA, USA, 3 Centers for Disease Control and Prevention, Atlanta, GA, USA OBJECTIVES: To evaluate the cost-effectiveness of 2009 pandemic influenza A(H1N1) (pH1N1) vaccination in various age and risk groups in the United States. METHODS: A computer simulation model was developed to predict costs and health outcomes for a pH1N1 vaccination program using inactivated vaccine compared to no vaccination. The modeled target population included hypothetical cohorts of persons aged 6 months and older stratified by age and risk. Probabilities, costs and quality-of-life weights were derived from emerging primary data on pH1N1 infections in the US, published and unpublished data for seasonal and pH1N1 illnesses, supplemented by expert opinion. The analysis used a one-year time horizon for most endpoints but also included longer-term costs and consequences of long-term sequelae and deaths. A societal perspective was used. The main endpoint was the incremental cost-effectiveness ratio in dollars per quality-adjusted life year (QALY) gained. Sensitivity analyses were conducted to evaluate the robustness of results as parameters were varied over plausible ranges, including a scenario analysis to evaluate the effect of timing of vaccination assuming a hypothetical 16-week flu season and normalized epidemic curve of illness. RESULTS: For vaccination initiated prior to the outbreak, pH1N1 vaccination was cost-saving for persons 6 months to 64 years with high risk conditions assuming a 15% overall attack rate. For those without high risk conditions, pH1N1 vaccination was not cost-saving but required a net investment; cost-effectiveness ratios ranged from $8,000-$52,000/QALY depending on age and risk category. Results were sensitive to the number of vaccine doses needed, costs of vaccination, illness rates, and timing of vaccine delivery. Cost-effectiveness ratios increased sub-stantially if vaccination were initiated after the 10 th week of the start of a hypothetical 16-week epidemic. CONCLUSIONS: Vaccination for pH1N1 for children and working-age adults is cost-effective compared to other preventive health interventions under a wide range of scenarios. (ICU) . METHODS: The pharmacoeconomic analysis utilized the cost-effectiveness analysis (CER). If the efficacy and the cost of any of the studied regimens exceeded those of the other regimen, an incremental analysis was carried out (ICERs). A list of direct costs was compiled: clinical laboratory procedures carried out at invasive candidiasis diagnosis; antimycotic costs in the treatment of invasive candidiasis; antimycotic administration costs; costs of the diagnosis of adverse events following administration of an antimycotic. Efficacy and safety data were based on additional analyses of a randomised, double blind, multinational trial of antimycotics. To evaluate the degree of inaccuracy of the results, sensitivity analyses were performed RESULTS: It was established that the mode of starting treatment of IC amphotericin B and then caspofungin was both more effective and less expensive in comparison with the use of amphotericin B and then amphotericin B lipid complex. When we used caspofungin or amphotericin B lipid complex shares of expenses on antimycotices were 80-87%. Lower parameters are received at application amphotericin B and fluconazole, 46 % and 66 %, accordingly. The analysis of the alternative, whose efficiency of treatment of IC was equal in all groups, has shown, that the least expensive strategy was that where the starting therapy was amphotericin B. The unilateral analysis of sensitivity proves that the efficiency of expenses of the treatment of IC was more sensitive to a parameter of efficiency than to the change of the expenses connected with the price of medicines. CONCLUSIONS: In modern Russian conditions, in view of a high level of resistance in vitro Candida spp. to fluconazole and high toxicity of amphotericin B, the most expedient strategy is that starting what the application of caspofungin.
PIN33 A CLINICAL-ECONOMIC STUDY OF CASPOFUNGIN THERAPY IN THE TREATMENT OF INVASIVE CANDIDIASIS IN RESUSCITATION AND INTENSIVE CARE UNITS
PIN34 COST MINIMIZATION ANALYSIS OF THREE CANDIDA IDENTIFICATION TESTS WITH PREDICTION MODELS BASED ON REAL-WORLD DATA
Yeh JY 1 , Sims SV 2 , Sekeres JK 1 , Neuner EA 1 , Shrestha NK 1 , Hall GS 1 , Procop GW 1 1 Cleveland Clinic, Cleveland, OH, USA, 2 Marymount Hospital, Garfield Heights, OH, USA OBJECTIVES: Candida species are a common cause of nosocomial bloodstream infection. Positive blood cultures or high clinical suspicion for candidemia prompt empiric antifungal therapy. Early species identification allows earlier initiation of appropriate therapy or de-escalation to less expensive narrow spectrum therapy. Our institute used Candida PNA-FISH (Test A) to rapidly differentiate Candida albicans from non-albicans species. Two newer tests can differentiate among albicans, glabrata or others (Candida PNA-FISH dual probe, Test B) and among albicans/parapsilosis, tropicalis, glabrata/krusei or others (Candida PNA-FISH Traffic Light, Test C). This study aimed to predict cost impacts if newer tests would have been used. METHODS: From a hospital administration perspective, a retrospective chart review of candidemic patients between January 2007 and May 2008 was conducted to obtain costs and utilization of antifungal medications and information on species identification. Monte Carlo simulation models with certain assumptions and limitations were created to predict costs. Model inputs were determined based on real-world data. Only antifungal medication costs, incorporating doses, frequencies and 2008 average wholesale prices, were considered. One-way and probabilistic sensitivity analyses (2,500 trials) were performed. RESULTS: There were 140 candidemic episodes in 132 patients. Candida species isolated included albicans (43%), glabrata (29%), parapsilosis (14%), tropicalis (6%), krusei (6%), and others. Compared to Test A, median potential cost savings per patient are $37 (95% CI $14-$104, Test B) and $51 (95% CI $22-$130, Test C). Minimal cost savings per patient are $24 (Test B) and $35 (Test C) at a probability of 80%. Two key variables were identified. Potential cost savings increase with increased empiric use of micafungin or decreased prevalence of Candida albicans. CONCLUSIONS: With sole consideration of antifungal medication costs, switching from Test A to Test C is likely to yield more cost savings than switching to Test B, but cost savings may not be substantial. by the FDA for the treatment of cSSSIs. This study investigated the economic implications of treating cSSSIs with ceftobiprole, compared to vancomycin or ceftazidime. METHODS: A discrete event simulation of acute anti-infective treatment in patients with cSSSI was developed. Three copies of patients were created. Each copy was assigned one of the treatments (ceftobiprole, vancomycin or ceftazidime). Patients' clinical course was simulated using data from clinical trials of ceftobiprole (patient and infection characteristics, cure rates, treatment duration, length of hospital stay, adverse event rates, treatment discontinuation, use of subsequent treatments). Pathogen coverage status was determined based on the extent to which the treatment can cover the pathogens causing the infection (MRSA only, Gram-positive non-MRSA, Gram-negative, and other possible combinations). Costs in 2007 USD were taken from published sources. Various events (relapse, treatment adjustment, and death) and the associated direct medical costs were estimated for a treatment episode (49 days). Results are based on 100 simulations of 1,000 patients each. RESULTS: The mean cost per patient was estimated to be $19,247 treated with ceftobiprole vs. $19,884 for vancomycin and $19,721 for ceftazidime. The frequencies of cure, relapse, and death were similar across the groups. Less than 1% of patients started on ceftobiprole required treatment escalation compared to 23% for vancomycin and ceftazidime, indicating that ceftobiprole provided broader coverage against the causing pathogens of cSSSIs, thus patients received adequate coverage more promptly. CONCLUSIONS: Using ceftobiprole for treatment of cSSSIs is expected to provide similar cure rates without increasing costs compared to vancomycin and ceftazidime in the US.
PIN35 ECONOMIC EVALUATION OF CEFTOBIPROLE FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS IN THE UNITED STATES
PIN36 THE IMPACT OF AGE DEPENDENT UTILITY ON THE COST EFFECTIVENESS OF PEGYLATED INTERFERON AND RIBAVIRIN VERSUS INTERFERON AND RIBAVIRIN AS THERAPY FOR GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C
McEwan P 1 , Yuan Y 2 , Townsend R 1 , Kim RW 3 1 CRC, Cardiff, UK, 2 Bristol-Myers Squibb Company, Plainsboro, NJ, USA, 3 Mayo Clinic College of Medicine, Rochester, MN, USA OBJECTIVES: It is common for published models describing the treatment effectiveness of managing chronic hepatitis C (CHC) to assume those subjects achieving a sustained virologic response (SVR) attain a health utility of one; equivalent to perfect health. Our objective was to evaluate the impact of utilising age dependent utility weights on the cost effectiveness obtained in a CHC model. METHODS: A Markov model describing the natural history of CHC in patients with genotype 1 was developed to estimate the cost effectiveness of treatment with peginterferon α-2a plus ribavarin (PEG) versus interferon α-2b plus ribavarin (IFN). The model was populated with data and validated using a previously published cost effectiveness model. The model was re-calibrated using age dependent utility weights for patients achieving SVR and run over a lifetime taking a payer perspective, with both costs and benefits discounted at 3.5%. RESULTS: The cost per quality adjusted life years (QALYs) of PEG versus IFN obtained using age independent SVR disease state utility value of one (base case) were: $1713 for those aged 40 years, $3935 for those aged 50 years, $8612 for those aged 60 years, and $18,485 for those aged 70 years. The same analysis performed using age dependent utility values were: $2,373 for those aged 40 years, $5,931 for those aged 50 years, $14,924 for those aged 60 years, and $46,123 for those aged 70 years. CONCLUSIONS: Health utility is an important driver of cost effectiveness in CHC economic models. Compared to the base case, age dependent utility weights substantially increase the cost effectiveness ratios, particularly in patients aged 60 years or over. The assumption that patients attaining SVR have perfect health has the potential to bias decision making and there is, therefore, a need for future research that better describes the utility profile associated with subjects achieving SVR.
PIN37 COST EFFECTIVENESS ANALYSES (CEA) OF LOPINAVIR/RITONAVIR (LPV/R) AND ATAZANAVIR PLUS RITONAVIR (ATV + RTV) REGIMENS FOR ANTIRETROVIRAL (ARV) NAÏVE HIV-1 INFECTED PATIENTS BASED ON CASTLE 48-WEEK STUDY: APPLICATION TO GERMANY, ITALY, SPAIN, AND THE UNITED KINGDOM
Simpson KN 1 , Dietz B 2 , Baran RW 3 , Kirbach SE 1 , Podsadecki T 3 1 Medical University of South Carolina, Charleston, SC, USA, 2 Abbott GmbH & Co. KG, Ludwigshafen, Germany, 3 Abbott Laboratories, Abbott Park, IL, USA OBJECTIVES: No differences in viral load (VL) or CD4 + T-cell count at 48 weeks were reported for the CASTLE study. However, total cholesterol (TC) levels were elevated in 7% and 18% of subjects receiving ATV + RTV and LPV/r, respectively. These measures can predict outcomes which affect the future cost of HIV in European health systems. Our objective was to examine expected CEA and budget impact of LPV/r vs. ATV + RTV for patients similar to the CASTLE population, for Germany, Italy, Spain, and UK. METHODS: Using a previously published Markov model of HIV disease and newly developed cost data, we compared the cost/QALY and budget impact of the two ARV regimens. This model used TC levels at 48 weeks and the Framingham equation to include effects of heart disease in the model. Costing used 2009 health services perspective. RESULTS: The CHD risk favored ATV + RTV, resulting in a life expectancy increase of 0.031 QALYs (11 days). Cost effectiveness ratios for ATV + RTV were: Germany 3239,700; Italy 3178,856; Spain 3200,531; UK £125,139 per QALY. Five year per-patient savings were estimated for LPV/r: Germany 34057; Italy 32681; Spain 33275; UK £1644. If all subjects were assumed to be smokers on anti-hypertensive medication, life expectancy improved by 0.088 QALYs (32 days) favoring ATV + RTV. However, the ICERs produced under this scenario were 396,812/QALY and £65,279/QALY in Germany and UK, respectively. CON-CLUSIONS: Based on these cost effectiveness ratios, selecting an ATV + RTV based regimen in ARV naïve populations with a CHD risk similar to subjects in the CASTLE study does not appear to be a cost effective use of scarce resources in any of the countries evaluated. Furthermore, costs associated with the very small added CHD risk incurred by LPV/r treatment are more than offset by its short and long term cost savings.
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COSTS OF RECRUITING PATIENTS WITH HIV INTO A RANDOMIZED CLINICAL TRIAL OF BEHAVIORAL INTERVENTIONS FOR ANTIRETROVIRAL MEDICATION ADHERENCE
Malewski D 1 , Rasu R 1 , Thomson N 2 , Banderas J 2 , Goggin K 2 1 University of Missouri Kansas City School of Pharmacy, Kansas City, MO, USA, 2 University of Missouri Kansas City, Kansas City, MO, USA OBJECTIVES: Analyze and identify total time and cost of recruiting patients into a randomized clinical trials(RCT) of Motivational Interviewing-based behavioral interventions to enhance antiretroviral therapy(ART) adherence. Despite numerous federally funded RCTs, little literature describes the cost of recruiting patients into behavioral interventions to enhance ART adherence. METHODS: A secondary data analysis of recruitment data collected for Project MOTIV8(R01 MH68197) was conducted. Data from 204 HIV+ patients recruited from the Kansas City metro area between June of 2004 and August of 2008 were examined for this cost analysis. Direct labor costs for all recruitment staff were collected. Microsoft® Excel spreadsheet was used to determine number of attempted recruits, average time spent to recruit/enroll a patient, number of successful enrollments, and project resources spent on recruitment. Discounting and sensitivity analysis was done to determine the robustness of this cost analysis. RESULTS: Over four years Project MOTIV8 screened 1710 patients and successfully enrolled 204 participants (11.9%) into the study. The ratio of patients approached to successfully enroll was 8.38:1. Ten minutes was the average time spent to recruit a patient, however it required 1.4 hours of effort to enroll an eligible patient in the study. All costs are reported in 2008 dollar value. The total cost associated with four staff members working on the recruitment effort came to $245,626.70(285 hours) over the study period. The cost for attempted recruitment was $143.64(10 minute average) and the cost for successful enrollment was $1204.05(1.4 hours) for patients with HIV. CONCLUSIONS: The costs associated with recruiting participants into a study are often overlooked and underestimated. This economic analysis can serve as a guide to determine the budget for actively enrolling patients with specific risk behaviors. This data provides information for understanding ancillary costs and will help to shed light on unique challenges in the HIV business environment.
INFECTION -Patient-Reported Outcomes Studies
PIN39 A RETROSPECTIVE EVALUATION OF PATIENT ADHERENCE TO ANTIRETROVIRAL THERAPY: PROPORTION OF DAYS COVERED VERSUS MEDICATION POSSESSION RATIO
Fowler JA 1 , Barner J 2 , Crismon ML 2 , Argo TR 3 , Smith TL 4 1 University of Iowa Hospitals and Clinics, Iowa City, IA, USA, 2 University of Texas at Austin, Austin, TX, USA, 3 Iowa VA Medical Center, Iowa City, IA, USA, 4 Seton Shoal Creek Hospital, Austin, TX, USA OBJECTIVES: The primary purpose of this study was to determine the relationship between psychotropic medication use and adherence to combination antiretroviral therapy. As a secondary analysis, adherence to combination antiretroviral therapy as measured by proportion of days covered (PDC) was compared to adherence based on the medication possession ratio (MPR) in order to facilitate comparison between the results of this study and those of previous studies evaluating antiretroviral adherence. METHODS: Data were extracted from Texas Medicaid files. Included subjects were adults with prescription claims for at least three antiretroviral medications indicated for treatment of HIV infection within a 3-month period between 1/1/2004 and 12/31/2004. PDC was defined as the total number of days during the 12-month followup period for which all index antiretroviral medications were available divided by 365 days, while MPR was defined as the average number of days supplied for all antiretroviral medications divided by 365 days (truncated at 100%). Data were analyzed using descriptive statistics. RESULTS: When measured by PDC, the mean adherence to combination antiretroviral therapy across the entire sample (N = 1,321) was 39.1% ± 34.6%. Mean adherence was markedly greater when measured by MPR at 70.4% ± 33.5%, with a mean difference between the two measures of 31.4% ± 36.8%. CONCLUSIONS: PDC provides a more conservative estimate of adherence to combination antiretroviral therapy than MPR. MPR results indicate that adherence in this study was similar to that found in previous studies using prescription claims data to evaluate adherence to combination antiretroviral therapy using modified versions of the MPR (72-81%). Use of PDC to calculate adherence to combination antiretroviral therapy may provide more clinically relevant information than other measures since concomitant use of all medications in the regimen is theoretically required for synergistic viral suppression and optimal HIV outcomes.
